Yahoo
Tokyo - Delayed Quote JPY

Taiko Pharmaceutical Co.,Ltd. (4574.T)

260.00 +2.00 (+0.78%)
At close: October 30 at 3:30:00 PM GMT+9
Chart Range Bar
Loading chart for 4574.T
  • Previous Close 258.00
  • Open 258.00
  • Bid 258.00 x --
  • Ask 261.00 x --
  • Day's Range 258.00 - 262.00
  • 52 Week Range 246.00 - 317.00
  • Volume 61,600
  • Avg. Volume 118,936
  • Market Cap (intraday) 13.08B
  • Beta (5Y Monthly) 0.32
  • PE Ratio (TTM) 19.01
  • EPS (TTM) 13.68
  • Earnings Date (est.) --
  • Forward Dividend & Yield 3.50 (1.35%)
  • Ex-Dividend Date Dec 29, 2026
  • 1y Target Est --

Taiko Pharmaceutical Co.,Ltd. manufactures and sells over-the-counter (OTC) medicines and quasi drugs in Japan and internationally. The company provides OTC medicines under the SEIROGAN, SEIROGAN TOI A and SEIROGAN Quick C, PISHUT OD Tablet brand names; and quasi-drugs under the RAPPA INTESTINAL REGULATOR BF brand names. It offers sanitation control products under the Cleverin PR, Cleverin Pro Stick, and Cleverin Pro name. In addition, the company manufactures and sells wood vinegar-based products. It exports its products. The company was incorporated in 1946 and is headquartered in Osaka, Japan.

www.seirogan.co.jp

220

Full Time Employees

December 31

Fiscal Year Ends

Healthcare

Sector

Recent News

View More

Performance Overview

Trailing total returns as of 10/30/2026, which may include dividends or other distributions. Benchmark is Nikkei 225 (^N225) .

YTD Return

4574.T
12.75%
Nikkei 225 (^N225)
25.73%

1-Year Return

4574.T
5.07%
Nikkei 225 (^N225)
23.31%

3-Year Return

4574.T
18.34%
Nikkei 225 (^N225)
106.18%

5-Year Return

4574.T
67.46%
Nikkei 225 (^N225)
119.05%

Earnings Trends

View More

Earnings Per Share (GAAP)

Revenue vs. Earnings

Annual
Quarterly
Annual
Quarterly
Q1 FY26
Revenue 916M
Earnings -95M
Profit Margin -10.37%

Q2

FY25

Q3

FY25

Q4

FY25

Q1

FY26

0
500M
1B
2B
2B
-10.0%
0.0%
10.0%
20.0%

Statistics

View More

Valuation Measures

Annual
  • Market Cap

  • Enterprise Value

  • Trailing P/E

  • Forward P/E

  • PEG Ratio (current)

  • Price/Sales (ttm)

  • Price/Book (mrq)

  • Enterprise Value/Revenue

  • Enterprise Value/EBITDA

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    10.39%

  • Return on Assets (ttm)

    2.36%

  • Return on Equity (ttm)

    8.40%

  • Revenue (ttm)

    6.62B

  • Net Income Avi to Common (ttm)

    688M

  • Diluted EPS (ttm)

    13.68

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    3.17B

  • Total Debt/Equity (mrq)

    1.41%

  • Levered Free Cash Flow (ttm)

    237.25M

Company Insights

Research Reports

View More

People Also Watch

Mobilize your Website
View Site in Mobile | Classic
Share by: